PCSA Stock — Processa Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a publicly listed clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules, one of which is currently in a Phase 2 trial.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.90

Market cap

$5.3M

Cash

$0.2M

Enterprise value

$5.1M

Balance sheet

Cash	$0.2M
Debt	$0.0M
Net cash	$0.2M
Enterprise value	$5.1M
Basic shares	2.8M shares
Fully diluted shares	4.4M shares
Fully diluted market cap	$8.4M
Cash per share	$0.07
Quarterly burn	$2.0M
Cash runway	0.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

2.8M

Pre-funded warrants

0.0M

Options

—

RSUs

—

Warrants

1.6M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

4.4M

Cap table as of 2026-08-07.

Price history

Loading PCSA daily closes…

Loading price history…

Next catalyst

PCS6422 and capecitabine · Now - Nov 24, 2026 Now · Phase 2 · Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	PCS6422 and capecitabine	Phase 2	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VT-7208

Phase 2 · Active Modality: oral small molecule

Target Bruton’s tyrosine kinase (BTK)

Partnerships Vidya: lead asset acquired in Vidya Acquisition (Jul 2026); $200M concurrent private placement funds operations into H2 2029

Indications

Food allergy (Phase 2)
Chronic spontaneous urticaria (CSU) (Phase 2)
Relapsing multiple sclerosis (RMS) (Phase 2)

Catalysts

— second half of 2027
— first half of 2028
— second half of 2028

Status note Majority of resources now focused on VT-7208; Phase 2 proof-of-concept studies being initiated in food allergy and CSU.

PCS6422

Phase 2 · Terminated

Aliases NGC-Cap (PCS6422 + capecitabine)

Target DPD

Partnerships Elion Oncology: license terminated and program returned to Elion (settlement Jul 23, 2026); Processa paid $650k and agreed to grant Elion a 7.5% non-voting equity interest

Indications

Advanced/metastatic breast cancer (Phase 2)

Status note Ongoing NGC-Cap Phase 2 trial being closed following termination of the Elion license agreement and return of the program to Elion.

PCS499

Stage not disclosed · Active

Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.

PCS12852

Stage not disclosed · Active

Target 5-HT4 receptor (5HT4 agonist)

Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.

PCS11T

Stage not disclosed · Active

Target topoisomerase I (SN38 analog)

Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PCS6422 and capecitabine
Lead indication	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06568692	Phase 2	Recruiting	Sponsor	Processa Pharmaceuticals	—	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Processa Pharmaceuticals on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	55,000	no change	0.08%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PCSA — Processa Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

PCSA — Processa Pharmaceuticals Inc.